|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Agboola O: Adjuvant treatment in gastric
cancer. Cancer Treat Rev. 20:217–240. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cunningham D, Allum WH, Stenning SP, et
al: Perioperative chemotherapy versus surgery alone for resectable
gastroesophageal cancer. N Engl J Med. 355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cosse JP and Michiels C: Tumour hypoxia
affects the responsiveness of cancer cells to chemotherapy and
promotes cancer progression. Anticancer Agents Med Chem. 8:790–797.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Griffiths EA, Pritchard SA, Welch IM,
Price PM and West CM: Is the hypoxia-inducible factor pathway
important in gastric cancer? Eur J Cancer. 41:2792–2805. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu L, Ning X, Sun L, et al:
Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced
chemoresistance in gastric cancer. Cancer Sci. 99:121–128.
2008.
|
|
8
|
Kang HC, Kim IJ, Park JH, Shin Y, Ku JL,
Jung MS, Yoo BC, Kim HK and Park JG: Identification of genes with
differential expression in acquired drug-resistant gastric cancer
cells using high-density oligonucleotide microarrays. Clin Cancer
Res. 10(1 Pt 1): 272–284. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mathew ST, Devi SG, Prasanth VV and Vinod
B: Efficacy and safety of COX-2 inhibitors in the clinical
management of arthritis: Mini review. ISRN Pharmacol.
2011:4802912011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dannenberg AJ and Subbaramaiah K:
Targeting cyclooxygenase-2 in human neoplasia: rationale and
promise. Cancer Cell. 4:431–436. 2003. View Article : Google Scholar
|
|
11
|
Schönthal AH: Direct non-cyclooxygenase-2
targets of celecoxib and their potential relevance for cancer
therapy. Br J Cancer. 97:1465–1468. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chuang HC, Kardosh A, Gaffney KJ, Petasis
NA and Schönthal AH: COX-2 inhibition is neither necessary nor
sufficient for celecoxib to suppress tumor cell proliferation and
focus formation in vitro. Mol Cancer. 7:382008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yoshida K, Yamaguchi K, Osada S, Kawaguchi
Y, Takahashi T, Sakashita F and Tanaka Y: Challenge for a better
combination with basic evidence. Int J Clin Oncol. 13:212–219.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jordan CT, Guzman ML and Noble M: Cancer
stem cells. N Engl J Med. 355:1253–1261. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mayer A and Vaupel P: Hypoxia, lactate
accumulation, and acidosis: siblings or accomplices driving tumor
progression and resistance to therapy? Adv Exp Med Biol.
789:203–209. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Covello KL, Kehler J, Yu H, Gordan JD,
Arsham AM, Hu CJ, Labosky PA, Simon MC and Keith B: HIF-2alpha
regulates Oct-4: effects of hypoxia on stem cell function,
embryonic development, and tumor growth. Genes Dev. 20:557–570.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu L, McArthur C and Jaffe RB: Ovarian
cancer stem-like side-population cells are tumourigenic and
chemoresistant. Br J Cancer. 102:1276–1283. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Martin CM, Ferdous A, Gallardo T,
Humphries C, Sadek H, Caprioli A, Garcia JA, Szweda LI, Garry MG
and Garry DJ: Hypoxia-inducible factor-2alpha transactivates Abcg2
and promotes cytoprotection in cardiac side population cells. Circ
Res. 102:1075–1081. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nichols J, Zevnik B, Anastassiadis K, Niwa
H, Klewe-Nebenius D, Chambers I, Schöler H and Smith A: Formation
of pluripotent stem cells in the mammalian embryo depends on the
POU transcription factor Oct4. Cell. 95:379–391. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tai MH, Chang CC, Kiupel M, Webster JD,
Olson LK and Trosko JE: Oct4 expression in adult human stem cells:
evidence in support of the stem cell theory of carcinogenesis.
Carcinogenesis. 26:495–502. 2005. View Article : Google Scholar
|
|
22
|
Dallas NA, Xia L, Fan F, et al:
Chemoresistant colorectal cancer cells, the cancer stem cell
phenotype, and increased sensitivity to insulin-like growth
factor-I receptor inhibition. Cancer Res. 69:1951–1957. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang XQ, Feng YG, Wu MY, Bai HX and Wang
XY: The effect of 5-Fu on the ratio of SP cells and the expression
of HIF-2α and ABCG2 in gastric cancer SGC7901 cell line under
hypoxia. World Chinese Journal of Digestology. 20:1813–1818.
2012.
|
|
24
|
Rosas C, Sinning M, Ferreira A, Fuenzalida
M and Lemus D: Celecoxib decreases growth and angiogenesis and
promotes apoptosis in a tumor cell line resistant to chemotherapy.
Biol Res. 47:272014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Steinbach G, Lynch PM, Phillips RK, et al:
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial
adenomatous polyposis. N Engl J Med. 342:1946–1952. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li M, Lotan R, Levin B, Tahara E, Lippman
SM and Xu XC: Aspirin induction of apoptosis in esophageal cancer:
a potential for chemoprevention. Cancer Epidemiol Biomarkers Prev.
9:545–549. 2000.PubMed/NCBI
|
|
27
|
Kuo CH, Hu HM, Tsai PY, et al: Short-term
celecoxib intervention is a safe and effective chemopreventive for
gastric carcinogenesis based on a Mongolian gerbil model. World J
Gastroenterol. 15:4907–4914. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rocha FT, Lourenço LG, Jucá MJ, Costa V
and Leal AT: Chemoprevention by celecoxib in reflux-induced gastric
adenocarcinoma in Wistar rats that underwent gastrojejunostomy.
Acta Cir Bras. 24:189–194. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tang C, Liu C, Zhou X and Wang C: Enhanced
inhibitive effects of combination of rofecoxib and octreotide on
the growth of human gastric cancer. Int J Cancer. 112:470–474.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dandekar DS, Lopez M, Carey RI and
Lokeshwar BL: Cyclooxygenase-2 inhibitor celecoxib augments
chemotherapeutic drug-induced apoptosis by enhancing activation of
caspase-3 and -9 in prostate cancer cells. Int J Cancer.
115:484–492. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ding H, Han C, Zhu J, Chen CS and
D’Ambrosio SM: Celecoxib derivatives induce apoptosis via the
disruption of mitochondrial membrane potential and activation of
caspase 9. Int J Cancer. 113:803–810. 2005. View Article : Google Scholar
|
|
32
|
Kim N, Kim CH, Ahn DW, et al: Anti-gastric
cancer effects of celecoxib, a selective COX-2 inhibitor, through
inhibition of Akt signaling. J Gastroenterol Hepatol. 24:480–487.
2009. View Article : Google Scholar
|
|
33
|
Swamy MV, Herzog CR and Rao CV: Inhibition
of COX-2 in colon cancer cell lines by celecoxib increases the
nuclear localization of active p53. Cancer Res. 63:5239–5242.
2003.PubMed/NCBI
|
|
34
|
Erkinheimo TL, Lassus H, Finne P, van Rees
BP, Leminen A, Ylikorkala O, Haglund C, Butzow R and Ristimäki A:
Elevated cyclooxygenase-2 expression is associated with
alteredexpression of p53 and SMAD4, amplification of HER-2/neu, and
poor outcome in serous ovarian carcinoma. Clin Cancer Res.
10:538–545. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Krysan K, Merchant FH, Zhu L, et al:
COX-2-dependent stabilization of survivin in non-small cell lung
cancer. FASEB J. 18:206–208. 2004.
|
